Nanomaterials In Drugs To Get Risk-Based Oversight
Executive Summary
US FDA draft guidance advises manufacturers to use 11 risk factors in evaluating the use of nanomaterials in drug products. It also urges manufacturers to pay close attention to excipients.
You may also be interested in...
US FDA Adds Generic Insights On How To Demonstrate Nanomaterials Quality
Document sets final framework for assessing chemistry, manufacturing, controls and bioequivalence of a wide range of nanomaterials with new advice such as focusing analysis on the right therapeutic moiety.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.